Abstract

A method of diagnosing pancreatic ductal adenocarcinoma (PDAC) is disclosed The method comprises detecting the presence of autoantibodies in a biological sample from a subject which bind to LEMD1 and MAGEB1 antigens. The method optionally also comprises detecting autoantibodies from one or more additional antigens selected from ACVR2B, GAGE1, TSGA10, PAGE1, BAGE4, AURKA, MAGEA10, PLEKHA5, PLK4 and XAGE3Av1. The autoantibodies can be detected by contacting the sample with immobilized LEMD1 and MAGEBB1, and optionally any other antigens listed above, so that any autoantibodies in the sample bind to the antigens. Detection antibodies, e.g. labeled anti-human IgG or IgA antibodies, can then be used to detect the bound autoantibodies, for example in a sandwich assay. Antigen complexes, a kit and a computer-implemented method of diagnosing PDAC are also disclosed.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Mycobacterium tuberculosisM. tbM. tbM. tbM. tbM. tb biomarkers in a sample from a subject.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Described herein are vaginal live biotherapeutic compositions for treatment of vaginal dysbiosis or conditions/disorders associated with vaginal dysbiosis. Also disclosed herein are methods for treating vaginal dysbiosis in an individual in need thereof, methods for reducing the risk of vaginal dysbiosis in an individual in need thereof, and methods for restoring Lactobacillus dominated microbiota in an individual in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

in vitroin vitro methods of diagnosis of active TB and to an immunoassay device which incorporates the antibody.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

invitrovitro methods of diagnosis of active TB and to an immunoassay device which incorporates the antibody.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure relates to chimeric human papillomavirus (HPV) compositions for use in preventing infectious diseases. The present disclosure also relates to methods of generating chimeric HPV compositions using transgenic plant methods.

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61P 31/04 - Antibacterial agents
• C12N 15/83 - Viral vectors, e.g. cauliflower mosaic virus
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

There is disclosed a wireless power transfer apparatus (10, 100, 200, 2500) including at least one non-planar flux coupling structure (12, 112, 212, 213). The non-planar flux coupling structure may include a first set of coil portions (14, 114, 214, 2014, 3014) spaced along a first axis (A, A1, A2), and a second set of coil portions (16, 116, 216, 2016, 3016) spaced along a second axis (B, B1, B2). The first and second sets of coil portions may be at least partially disposed in or on a curved or non-planar surface (18, 118, 218). The first axis and second axis may be tilted at opposite angles (α, β, α1, β1).

IPC Classes  ?

• H01F 38/14 - Inductive couplings
• H01F 27/28 - CoilsWindingsConductive connections
• H01F 27/36 - Electric or magnetic shields or screens
• H01F 27/24 - Magnetic cores
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling

Abstract

A breakpoint cluster region-Abelson (Bcr-Abl) inhibitor for use in a method of treating a skin condition or disease, such as keloid disease (KD) or folliculitis keloidalis nuchae (FKN), is provided The Bcr-Abl inhibitor can be GNF-2, GNF-5 or ON012380. Optionally, the Bcr-Abl inhibitor can be administered in combination with one or more 4-anilinoquinazolines, such as dasatinib, nilotinib, bosutinib, axitinib, ponatinib, rociletinib, vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, lapatinib, sunitinib, sorafenib or pazopanib. A UDP- glucuronosyltransferase (UGT) inhibitor, such as magnolol, can also be administered in an optional second treatment step, typically about 2 to 4 weeks after the first treatment. One or more 4-anilinoquinazolines can also be administered in the second treatment step. A Bcr-Abl inhibitor and/or one or more 4-anilinoquinazolines can further be administered in an optional third treatment step, typically about 6 weeks after the first treatment. A method of treatment and a kit are also provided.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders

Abstract

A system and method for muscle activity monitoring are provided. The method includes transmitting, towards a selected muscle of interest of a human or animal body, via a wave transmitter, a signal comprising a series of chirps each having a sweep time configured for a duration of a muscle activation period. The muscle of interest is spaced apart from the wave transmitter. The method includes receiving, via a wave receiver spaced apart from the muscle of interest, a primary response signal including a reflection of the signal from the muscle of interest and comprising reflections of each of the chirps in the series of chirps. The method includes extracting, from the primary response signal, a primary phase signal based on a range between the receiver and the muscle of interest. The method includes outputting a movement signal representing muscle deformation of the selected muscle of interest. The movement signal is based on the primary phase signal.

IPC Classes  ?

• A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves using microwaves or terahertz waves
• G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systemsAnalogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

THIS invention relates to a cervical traction device, and more particularly but not exclusively to a cervical traction device suitable for use in correcting vertebral alignment of the cervical spinal column through flexion, extension and tension. The device includes a triangular base, with a displaceable arm extending from the base. The displaceable arm is both longitudinally and pivotably displaceable relative to the base, and has a free end that is connected to a tension transmission arrangement for transmitting a force to the head of a patient.

IPC Classes  ?

• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

The present invention relates to methods and systems for identification of differentially expressed targets for anticancer agents and/or identification of potential CSR-related off-target effects of anticancer agents in a subject. In particular, the methods and systems allow for the identification of anticancer drugs for the treatment of cancer in a subject which should not develop off-target effects.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of detecting and identifying an analyte in a sample is provided. The method comprises the steps of applying a sample to a Surface Enhanced Raman Scattering (SERS)-active surface comprising an electrode which is coated with polyelectrolyte-wrapped nanometallic particles; applying, in a step-wise manner, a first voltage and then a second voltage to the SERS-active surface; generating a SERS spectrum of the SERS-active surface; and determining whether the generated SERS spectrum is characteristic for a target analyte. The method can be used to diagnose and treat an infection. A SERS-active surface, kit and computer-implemented method for performing the above method are also provided.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 21/65 - Raman scattering
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A method of preparing a catalyst support structure for use in a catalytic reaction. According to the method, a mixed metal oxide compound which defines a crystal lattice is synthesized. Cations of at least one catalytic promoter element are dispersed within the compound and incorporated into the crystal lattice. The conditions of synthesis are preselected to inhibit destabilization of the catalyst support structure such that the structure remains stable against collapse and exsolution under reaction conditions associated with the catalytic reaction. The metal oxide compound may comprise an oxidic perovskite having the formula A(1-x)A′(x)B(1-y)B′yO3 wherein A and B represent metal cations and A′ and B′ represent cations of the promoter element or elements. Also provided is a catalyst support structure having cations of a promoter element incorporated into its crystal lattice. The support structure is stable against collapse and exsolution under reaction conditions.

IPC Classes  ?

• B01J 21/04 - Alumina
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 35/70 - Catalysts, in general, characterised by their form or physical properties characterised by their crystalline properties, e.g. semi-crystalline
• B01J 37/03 - PrecipitationCo-precipitation

Abstract

A continuous process for aerobic oxidation of methane. The process includes a reactor (10) comprising a bed of a metal-based catalyst (16), a methane feed stream (30) into the reactor (10), an oxygen feed stream (30) into the reactor (10), and a water feed stream (12) into the reactor (10). The methane is oxidised in a single step in the reactor (10) over the metal-based catalyst (16) in the presence of liquid water to produce a reaction product including compounds selected from formaldehyde, oligomers of formaldehyde, methanediol, and products of addition reactions between methanol and formaldehyde, and mixtures thereof.

IPC Classes  ?

• C07C 45/33 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 21/18 - Carbon
• B01J 23/42 - Platinum
• B01J 23/50 - Silver
• B01J 23/652 - Chromium, molybdenum or tungsten
• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B01J 37/18 - Reducing with gases containing free hydrogen
• C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only

Abstract

The present invention relates to self-replicating DNA expression vectors comprising elements from Beak and Feather Disease Virus (BFDV), including a BFDV LIR element comprising an origin of replication (Ori), genes encoding a BFDV Rep protein and a heterologous polypeptide of interest under the control of a mammalian promoter, wherein the Rep protein is capable of binding to the Ori to initiate replication of the expression vector. Pharmaceutical compositions and cells comprising the self-replicating vectors are also provided. The self-replicating vectors may be used in methods of inducing an immune response or expressing a polypeptide in a subject, or as an expression system.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C12N 15/86 - Viral vectors

Abstract

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of a quinoxaline derivative of Formula I which inhibits nuclear import protein, Kpnβ1, and a therapeutically effective amount of at least one platinum-based chemotherapeutic agent. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of the compound of Formula I and the at least one platinum-based chemotherapeutic agent administered alone. Formula I A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of a quinoxaline derivative of Formula I which inhibits nuclear import protein, Kpnβ1, and a therapeutically effective amount of at least one platinum-based chemotherapeutic agent. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of the compound of Formula I and the at least one platinum-based chemotherapeutic agent administered alone. Formula I

IPC Classes  ?

• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding chimeric proteins comprising antigens of Mycobacterium tuberculosis, immunogenic variants or fragments thereof is formulated and administered in a way that the antigens, variants or fragments are produced by cells of a subject.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61P 31/06 - Antibacterial agents for tuberculosis
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding antigens of Mycobacterium tuberculosis, immunogenic variants or fragments thereof is formulated and administered in a way that the antigens, variants or fragments are produced by cells of a subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis

Abstract

An implantable device for aiding in generating connective tissue between a pair of anatomical structures in a mammalian body is provided. The device includes an elongate, flexible tether which can be secured between the anatomical structures and which carries a scaffold which is generally porous so as to be capable of promoting tissue ingrowth and collagen deposition along its length. The scaffold extends along the tether for a sufficient distance so that it is securable in at least close proximity to an anatomical structure at either end. The pores in the scaffold extend through the scaffold and each has a diameter in the range of about 10 μm to about 200 μm. The length of the tether is selected to be a desirable maximum distance between the anatomical structures along a desired path when secured therebetween.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials
• A61B 17/24 - Surgical instruments, devices or methods for use in the oral cavity, larynx, bronchial passages or noseTongue scrapers

Abstract

This invention relates to a method for increasing the expression, increasing glycosylation efficiency, reducing plant specific modifications, reducing aggregation and/or promoting the correct folding and oligomerisation of a heterologous polypeptide of interest in a plant cell, preferably a complex glycoprotein, wherein the method comprises co-expressing the heterologous polypeptide of interest with (i) a polypeptide encoding a mammalian chaperone protein, (ii) a polypeptide which improves N-glycan occupancy in the heterologous polypeptide of interest, and (iii) a nucleic acid which interferes with an enzyme which is responsible for the formation of truncated glycans in the plant cell and thus reduces the formation of truncated glycans. The invention further relates to plant cells and plants which, either transiently or stably, co-express the heterologous polypeptide of interest, the mammalian chaperone protein, the polypeptide which improves glycan occupancy and nucleic acid.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Provided herein is a method for stabilising a single stranded RNA (ssRNA) by encapsidation of the ssRNA with a tobamovirus coat protein to obtain a pseudovirion (PsV), the method comprising expressing a tobamovirus coat protein and the ssRNA comprising a tobamovirus encapsidation origin (OriA), wherein the expressed tobamovirus coat protein interacts with the OriA sequence on the ssRNA to initiate encapsidation of the ssRNA by the tobamovirus coat protein, thereby forming a pseudovirion. The PsVs produced according to the method can be used as a diagnostic control composition, where the ssRNA is a sequence detected by a molecular diagnostic assay. The pseudovirions may also be used as a vaccine to elicit an immune response in a subject, and in pharmaceutical compositions to be administered to a subject.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention provides for compounds that are phenyl-pyrazolo[3,4- b]pyridine-4-carboxylic acid derivates for use as 5-alpha reductase antagonists, in particular as type 1 and type 2 antagonists. The invention further provides for pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions in the treatment of diseases or disorders, in particular but not exclusively, in the treatment of benign prostatic hyperplasia and androgenetic alopecia.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 5/28 - Antiandrogens
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

This invention relates to a recombinant LSDV vector comprising a cassette encoding a foot and mouth disease virus (FMDV) polyprotein and a modified FMDV 3C protease. The invention also relates to a composition containing the rLSDV vector and the cassette. The invention further relates to a dual vaccine against LSDV and FMDV.

IPC Classes  ?

• A61K 39/135 - Foot-and-mouth disease virus
• A61K 39/275 - Poxviridae, e.g. avipoxvirus
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

This invention relates to a recombinant LSDV (rLSDV) vector comprising a cassette encoding a bovine coronavirus (BCoV) consensus spike and consensus BCoV nucleocapsid protein. The invention also relates to compositions containing the rLSDV vector and the cassette. The invention further relates to a dual vaccine against LSDV and BCoV.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/275 - Poxviridae, e.g. avipoxvirus

Abstract

The technology provided herein relates to novel Pseudomonas exotoxin A enzymes (PEs); to nucleic acid molecules encoding said PEs, vectors, host cells containing the nucleic acids and methods for preparation and producing such PEs; compositions and methods for using said PEs for the treatment of diseases, in particular cancers especially including hematological and solid malignancies, chronic inflammatory diseases and allergies including allergic asthma.

IPC Classes  ?

• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C12N 9/10 - Transferases (2.)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12R 1/385 - Pseudomonas aeruginosa

Abstract

The technology provided herein relates to novel Pseudomonas exotoxin A enzymes (PEs); to nucleic acid molecules encoding said PEs, vectors, host cells containing the nucleic acids and methods for preparation and producing such PEs; compositions and methods for using said PEs for the treatment of diseases, in particular cancers especially including hematological and solid malignancies, chronic inflammatory diseases and allergies including allergic asthma.

IPC Classes  ?

• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C12N 9/10 - Transferases (2.)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12R 1/385 - Pseudomonas aeruginosa

Abstract

A method and system of calibration of one or more sensors are provided in a given environment. In a reliable calibration phase, in a first time period after calibration of the sensor, the method determines an environment response function based on a known sensor response function. The environment response function is a spatio-temporal response of the environment representing the environmental response operating on the event to result in the measurand field. Subsequently, in an unreliable calibration phase, in a second time period after the first time period, the method estimates a current sensor response function based on the environment response function determined in the reliable calibration phase. The method outputs a calibration function based on the estimated current sensor response function for updating calibration of the sensor.

IPC Classes  ?

• G01D 18/00 - Testing or calibrating apparatus or arrangements provided for in groups

Abstract

The present disclosure is directed to the use of microvirin-N in the detection of Mycobacterium tuberculosis infections.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to polygenic nucleic acid constructs comprising nucleotide sequences encoding Mycobacterium tuberculosis antigens and to mRNA vaccine constructs transcribed or obtained therefrom. Also provided are lipid nanoparticles including the mRNA vaccine constructs and vaccine compositions comprising the constructs described. The constructs, lipid nanoparticles containing them, and vaccine compositions described may be useful in methods for eliciting a protective immune response against Mycobacterium tuberculosis in a subject.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis

Abstract

The invention provides a method, device, kit and computer-implemented method for diagnosing (and optionally also treating) cancer. The method for diagnosing cancer comprises the step of testing a blood sample from a subject suspected of having cancer for the presence of Ipo5 (Importin 5) and at least one other biomarker, the at least one other biomarker being selected from Ran (Ras-related nuclear protein) and KpnB1 (Karyopherin beta 1). The blood sample may also be tested for additional biomarkers such as CRM1 (Cross-Reactive-Material-197), Kpna2 (Karyopherin alpha 2), CAS (Cellular apoptosis-susceptibility protein) and Transportin 1.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety radiolabeled with a radionuclide. Radiolabeled compounds of the invention may be used in targeted radionuclide therapy wherein a patient is treated with a compound of the invention comprising a diagnostic radionuclide to identify the presence of a cancer or disease, followed by treatment with a compound of the invention comprising a therapeutic radionuclide to treat said cancer or disease.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61P 35/00 - Antineoplastic agents

Abstract

LactobacillusLactobacillus dominated microbiota in an individual in need thereof.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/04 - Antibacterial agents

Abstract

A continuous process for aerobic oxidation of methane. The process includes a reactor (10) comprising a bed of a metal-based catalyst (16), a methane feed stream (30) into the reactor (10), an oxygen feed stream (30) into the reactor (10), and a water feed stream (12) into the reactor (10). The methane is oxidised in a single step in the reactor (10) over the metal-based catalyst (16) in the presence of liquid water to produce a reaction product including compounds selected from formaldehyde, oligomers of formaldehyde, methanediol, and products of addition reactions between methanol and formaldehyde, and mixtures thereof.

IPC Classes  ?

• C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
• C07C 31/04 - Methanol
• C07C 45/33 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties
• C07C 47/04 - Formaldehyde

Abstract

This invention relates to a recombinant LSDV vector encoding a consensus BEFV Gb protein and a BEFV M protein. The invention also relates to combinations of the BEFV Gb and M proteins and the LSDV vector, compositions containing the BEFV Gb protein, BEFV M protein, and the LSDV vector and vaccines containing the BEFV Gb and M proteins and the LSDV vector. The invention further relates to a dual vaccine containing the BEFV Gb and M proteins and a modified LSDV comprising a stabilised SOD-homolog (SODis) gene, methods of producing the BEFV Gb and M proteins and the recombinant LSDV and pharmaceutical compositions either comprising the recombinant LSDV vector encoding the BEFV Gb and BEFV M proteins. More specifically, the invention relates to a dual vaccine against lumpy skin disease virus and Bovine Ephemeral Fever virus.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/205 - Rhabdoviridae, e.g. rabies virus
• A61K 39/275 - Poxviridae, e.g. avipoxvirus
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/20 - Antivirals for DNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

A method of detecting and identifying an analyte in a sample is provided. The method comprises the steps of applying a sample to a Surface Enhanced Raman Scattering (SERS)-active surface comprising an electrode which is coated with polyelectrolyte-wrapped nanometallic particles; applying, in a step-wise manner, a first voltage and then a second voltage to the SERS-active surface; generating a SERS spectrum of the SERS-active surface; and determining whether the generated SERS spectrum is characteristic for a target analyte. The method can be used to diagnose and treat an infection. A SERS-active surface, kit and computer-implemented method for performing the above method are also provided.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 21/65 - Raman scattering
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of a quinoxaline derivative of Formula I which inhibits nuclear import protein, Kpnβ1, and a therapeutically effective amount of at least one platinum-based chemotherapeutic agent. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of the compound of Formula I and the at least one platinum-based chemotherapeutic agent administered alone. Formula I

IPC Classes  ?

• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to self-replicating DNA expression vectors comprising elements from Beak and Feather Disease Virus (BFDV), including a BFDV LIR element comprising an origin of replication (Ori), genes encoding a BFDV Rep protein and a heterologous polypeptide of interest under the control of a mammalian promoter, wherein the Rep protein is capable of binding to the Ori to initiate replication of the expression vector. Pharmaceutical compositions and cells comprising the self-replicating vectors are also provided. The self-replicating vectors may be used in methods of inducing an immune response or expressing a polypeptide in a subject, or as an expression system.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

This invention relates to a chimaeric BLV-Gag VLP which contains T. parva p67 and/or gp34 antigens on its surface, the invention also relates to vectors comprising nucleic acids encoding the BLV-Gag proteins; and T. parva p67 and/or T. parva gp34 proteins. The invention specifically relates to the chimaeric BLV-Gag VLPs described herein, methods of producing the chimaeric BLV-Gag VLPs and pharmaceutical compositions either comprising the chimaeric BLV-Gag VLPs and/or vectors comprising the nucleic acids encoding the recombinant proteins which make up the chimaeric BLV-Gag VLPs. More specifically, the invention relates to a lumpy skin disease virus vaccine encoding the chimaeric BLV-Gag VLPs of the invention.

IPC Classes  ?

• A61K 39/018 - Babesia antigens, e.g. Theileria antigens
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 33/00 - Antiparasitic agents

Abstract

33 wherein A and B represent metal cations and A' and B' represent cations of the promoter element or elements. Also provided is a catalyst support structure having cations of a promoter element incorporated into its crystal lattice. The support structure is stable against collapse and exsolution under reaction conditions.

IPC Classes  ?

• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 37/03 - PrecipitationCo-precipitation
• C07C 1/04 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon monoxide with hydrogen
• C10G 2/00 - Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon

Abstract

A ground reaction force plate apparatus and measuring system are provided. The apparatus includes a plate for receiving a force to be measured as applied by a subject to the plate and a plurality of load cells in an arrangement supporting the plate, each load cell being a single-axis sensor with the axis provided at an angle to a plane of the plate and oriented towards a centre of the plate. The load cells are configured to measure data relating to a force vector at the angled single-axis sensor when the subject applies a force to the plate. A data collection controller is provided for logging time series measurements of the load cells over a time in which the subject applies a force to the plate. The system applies machine learning processing to output the load cell measurements as a three-dimensional ground reaction force on the plate by a subject.

IPC Classes  ?

• G01L 5/16 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• G01G 19/00 - Weighing apparatus or methods adapted for special purposes not provided for in groups

Abstract

OriAOriAOriA sequence on the ssRNA to initiate encapsidation of the ssRNA by the tobamovirus coat protein, thereby forming a pseudovirion. The PsVs produced according to the method can be used as a diagnostic control composition, where the ssRNA is a sequence detected by a molecular diagnostic assay. The pseudovirions may also be used as a vaccine to elicit an immune response in a subject, and in pharmaceutical compositions to be administered to a subject.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

This invention relates to a method for increasing the expression, increasing glycosylation efficiency, reducing plant specific modifications, reducing aggregation and/or promoting the correct folding and oligomerisation of a heterologous polypeptide of interest in a plant cell, preferably a complex glycoprotein, wherein the method comprises co-expressing the heterologous polypeptide of interest with (i) a polypeptide encoding a mammalian chaperone protein, (ii) a polypeptide which improves N-glycan occupancy in the heterologous polypeptide of interest, and (iii) a nucleic acid which interferes with an enzyme which is responsible for the formation of truncated glycans in the plant cell and thus reduces the formation of truncated glycans. The invention further relates to plant cells and plants which, either transiently or stably, co-express the heterologous polypeptide of interest, the mammalian chaperone protein, the polypeptide which improves glycan occupancy and nucleic acid.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12P 21/00 - Preparation of peptides or proteins

Abstract

The present invention relates to methods and systems for identification of differentially expressed targets for anticancer agents and/or identification of potential CSR-related off-target effects of anticancer agents in a subject. In particular, the methods and systems allow for the identification of anticancer drugs for the treatment of cancer in a subject which should not develop off-target effects.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention provides a user-guidance device for informing a required change to a pump volume displacement parameter of a manual drug infusion pump assembly, for use with manually-controlled infusion of a drug into a patient. The user-guidance device comprises a measurement component arranged to measure the pump volume displacement parameter. The device further comprises a computing device arranged to calculate a measured rate of infusion of the drug based on the measured pump volume displacement parameter; and to calculate with reference to said measured rate of infusion and to at least one model selected from the group consisting of pharmacokinetic and pharmacodynamic models, a model-simulated drug concentration in the patient. The computing device may be arranged to derive user-guidance information based on the model-simulated drug concentration. The invention also provides a drug infusion system which includes the disclosed user-guidance device in combination with a manual drug infusion pump assembly.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

A knee brace having an upper part securable about a user's thigh and a lower part securable about the user's lower leg is provided. The upper and lower parts are secured together adjacent the user's knee by a hinge. The knee brace is characterised in that a flexible tensioning element extends between the upper part and the lower part over a lobe which is secured to the upper part adjacent the hinge such that pivoting of the upper and lower parts about the hinge causes the flexible element to engage the lobe about its periphery to cause tension in the flexible element and wherein the lobe is shaped to cause the tension to dynamically increase as the upper part is pivoted relative to the lower part.

IPC Classes  ?

• A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces

Abstract

The present invention relates to a polygenic DNA construct consisting of three abiotic stress tolerance genes, separated by nucleic acids encoding FMDV 2A peptides under the control of a stress inducible promoter. The stable insertion of the construct into plants confers drought tolerance to the plants. The invention also provides for vectors, host cells, transgenic plants and transgenic seeds containing the construct.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention provides a method, device, kit and computer- implemented method for diagnosing (and optionally also treating) cancer. The method for diagnosing cancer comprises the step of testing a blood sample from a subject suspected of having cancer for the presence of Ipo5 (Importin 5) and at least one other biomarker, the at least one other biomarker being selected from Ran (Ras-related nuclear protein) and KpnBl (Karyopherin beta 1). The blood sample may also be tested for additional biomarkers such as CRM1 (Cross- Reactive-Material-197), Kpna2 (Karyopherin alpha 2), CAS (Cellular apoptosis-susceptibility protein) and Transportin 1.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure is directed to the use of microvirin-N in the detection of Mycobacterium tuberculosis infections.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)

Abstract

A system and method for determining currents for injection into or extraction from a power network are provided. In a method conducted at a point of common coupling to the network, Thévenin parameter data structures for each of a Thévenin voltage, resistance and inductance, are compiled. An offset data structure including offset values is compiled for application to corresponding values of the Thévenin voltage data structure to output an offset Thévenin voltage data structure. Offset values are calculated to satisfy physical constraints associated with the network. An optimal point of common coupling power data structure and the offset Thévenin voltage data structure are used to calculate current components for determining current for injection into or extraction from corresponding lines at the point of common coupling to reduce total electrical transmission losses of the network. The method may use the frequency domain and may include using frequency-dependent Thévenin parameters.

IPC Classes  ?

• H02J 3/06 - Controlling transfer of power between connected networksControlling sharing of load between connected networks
• H02J 3/46 - Controlling the sharing of output between the generators, converters, or transformers

Abstract

A body temperature measurement device includes a handle having a power supply for powering power its electronic components. A probe extends from the handle and has temperature sensors arranged along its length. The temperature sensors, as well as an orientation sensor provided in the handle, are in communication with a processor configured to communicate the temperatures and orientation sensor measurements to a remote computing device. A method for determining a time of death includes receiving temperature measurements of adjacent sites within a corpse and selecting a 3D human computational phantom corresponding to the corpse. Heat transfer from the corpse subsequent to death is simulated using the phantom and temperatures are calculated for the sites over candidate post-mortem intervals (PMIs). The calculated and measured temperatures are compared and a final PMI estimate outputted based on a candidate PMI resulting in a correlation between the calculated and measured temperatures.

IPC Classes  ?

• A61B 5/01 - Measuring temperature of body parts
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies

Abstract

An assistive device for a metered dose inhaler decreases the force required to operate the inhaler. The assistive device has a body with a passage for receiving a replaceable conventional metered dose inhaler assembly that has a canister and a transverse mouthpiece with an axis of the canister aligning approximately with that of the passage. At least two symmetrically arranged levers extend in a direction away from the body and parallel to an axis thereof. A proximal end of each lever is attached to the body such that the free opposite ends of the levers may be moved towards and away from each other. An inwardly directed cam surface on each of the lever exerts a force on an end of the canister in use to move the canister longitudinally to cause a dose of medicament to be dispensed from the canister. An optional dose counter may form part of the device.

IPC Classes  ?

• A61M 15/00 - Inhalators

Abstract

This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety radiolabeled with a radionuclide. Radiolabeled compounds of the invention may be used in targeted radionuclide therapy wherein a patient is treated with a compound of the invention comprising a diagnostic radionuclide to identify the presence of a cancer or disease, followed by treatment with a compound of the invention comprising a therapeutic radionuclide to treat said cancer or disease.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

The invention relates to a matrix-mediated algal cell culture system comprising a porous matrix, a microalgal cell culture comprising cells immobilised on the porous matrix, and a vector including a nucleic acid sequence encoding a heterologous polypeptide of interest, wherein immobilisation of microalgal cells on the porous matrix results in the formation of interstitial spaces between the microalgal cells to allow for increased contact of the microalgal cells with the vector compared with a culture of microalgal cells which are not immobilised on a porous matrix, thereby allowing for more efficient transfection of the microalgal cells with the vector. The invention also relates to methods of screening single species of microalgae and mixed ecology samples for the ability to be transfected using the algal cell culture system, and to methods for the production of heterologous polypeptides using the matrix-mediated cell culture system.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/14 - Plant cells

Abstract

This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides for a low pressure, low temperature process for the production of middle distillate products, including aviation fuel and diesel, from the hydrocracking of a hydrocarbon feedstock consisting of a mixture of hydrocarbons, wherein a significant fraction of said mixture is C25+ hydrocarbons including hydrocarbons selected from Fischer-Tropsch wax, long chain paraffin and/or olefin, wherein the feedstock may include a water component.

IPC Classes  ?

• C10G 47/18 - Crystalline alumino-silicate carriers the catalyst containing platinum group metals or compounds thereof
• B01J 29/44 - Noble metals
• B01J 29/74 - Noble metals

Abstract

This invention relates to a recombinant polypeptide encoding the SARS-CoV-2 spike protein candidate vaccine. The invention also relates to vectors comprising nucleic acids encoding the recombinant polypeptide. The invention specifically relates to the recombinant proteins described herein, methods of producing the recombinant proteins and pharmaceutical compositions either comprising the recombinant proteins and/or vectors comprising a nucleic acid encoding the recombinant protein. More specifically, the invention relates to a DNA vaccine, modified vaccinia Ankara virus vaccine and/or a lumpy skin disease virus vaccine encoding the recombinant protein of the invention.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

An implantable device for aiding in generating connective tissue between a pair of anatomical structures in a mammalian body is provided. The device includes an elongate, flexible tether which can be secured between the anatomical structures and which carries a scaffold which is generally porous so as to be capable of promoting tissue ingrowth and collagen deposition along its length. The scaffold extends along the tether for a sufficient distance so that it is securable in at least close proximity to an anatomical structure at either end. The pores in the scaffold extend through the scaffold and each has a diameter in the range of about 10 μm to about 200 μm. The length of the tether is selected to be a desirable maximum distance between the anatomical structures along a desired path when secured therebetween.

IPC Classes  ?

• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/06 - NeedlesHolders or packages for needles or suture materials
• A61B 17/24 - Surgical instruments, devices or methods for use in the oral cavity, larynx, bronchial passages or noseTongue scrapers
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Methods of producing bovine papillomavirus (BPV) virus-like particles and/or pseudovirions in plant cells have been identified. In some embodiments the methods can be used to produce plant-produced BPV VLPs and pseudovirions. Further provided are pharmaceutical compositions comprising the plant produced BPV VLPs and pseudovirions. In some embodiments the plant-produced BPV VLPs and pseudovirions, or the pharmaceutical compositions may be useful in neutralisation assays.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

in vitro in vitro methods for the extracellular production of African Horse Sickness Virus (AHSV) virus like particles (VLPs). AHSV virus like particles per se and to methods of preventing African Horse Sickness. The invention also relates to use of AHSV VLPs in the prevention of African Horse Sickness.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A61K 39/12 - Viral antigens

Abstract

A wireless radio frequency triggered signal acquisition device includes three orthogonal pick up coils in which voltages will be induced by a time varying, spatially varying magnetic field inside a chamber of an MRI scanner. A radio frequency detection circuit detects radio frequency pulses emitted by an MRI scanner and a wireless transmission circuit transmits data from the device. A 3-axis magnetometer is used for measuring magnetic flux in the chamber of the MRI scanner. A processor uses the detected radio frequency pulses to synchronize measurements taken by the magnetometer and pickup coils to a time frame of a gradient driver hardware, thereby matching the measurements to a pulse sequence waveform. The processor further combines measurements of induced voltages in the orthogonal pick up coils and the magnetic flux with the pulse sequence waveform in order to solve for the instantaneous position and orientation of the device.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux
• G01R 33/07 - Hall-effect devices
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• H01Q 1/27 - Adaptation for use in or on movable bodies
• H01Q 7/00 - Loop antennas with a substantially uniform current distribution around the loop and having a directional radiation pattern in a plane perpendicular to the plane of the loop

Abstract

An assistive device for a metered dose inhaler decreases the force required to operate the inhaler. The assistive device has a body with a passage for receiving a replaceable conventional metered dose inhaler assembly that has a canister and a transverse mouthpiece with an axis of the canister aligning approximately with that of the passage. At least two symmetrically arranged levers extend in a direction away from the body and parallel to an axis thereof. A proximal end of each lever is attached to the body such that the free opposite ends of the levers may be moved towards and away from each other. An inwardly directed cam surface on each of the levers engages a closed end of a canister in use to move the canister longitudinally to cause a dose of medicament to be dispensed from the canister. An optional dose counter may form part of the device.

IPC Classes  ?

• A61M 15/00 - Inhalators

Abstract

A sensor for monitoring utility poles includes a sensing module to detect a physical quantity from a utility pole or a conductor supported by a utility pole to which the sensor is attached in use. A power supply supplies power to the device and a memory for storing sensor data. A communications module is used for transmitting and receiving sensor data to and from one or more sensors which are attached to other utility poles located adjacent to or nearby the utility pole. A processor uses the detected sensor data together with received sensor data to calculate if the utility pole to which the sensor is attached has changed its physical condition, and wherein if the processor calculates that the utility pole to which the sensor is attached has changed its physical condition, a message is transmitted via the communications module to a remote server.

IPC Classes  ?

• H02J 13/00 - Circuit arrangements for providing remote indication of network conditions, e.g. an instantaneous record of the open or closed condition of each circuitbreaker in the networkCircuit arrangements for providing remote control of switching means in a power distribution network, e.g. switching in and out of current consumers by using a pulse code signal carried by the network
• G01P 13/00 - Indicating or recording presence or absence of movementIndicating or recording of direction of movement
• G01P 15/00 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration
• G01R 15/20 - Adaptations providing voltage or current isolation, e.g. for high-voltage or high-current networks using galvano-magnetic devices, e.g. Hall-effect devices
• G01R 19/00 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof
• G01R 31/08 - Locating faults in cables, transmission lines, or networks

Abstract

The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/10 - Transferases (2.)
• C12N 15/62 - DNA sequences coding for fusion proteins
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

A ground reaction force plate apparatus and measuring system are provided. The apparatus includes a plate for receiving a force to be measured as applied by a subject to the plate and a plurality of load cells in an arrangement supporting the plate, each load cell being a single-axis sensor with the axis provided at an angle to a plane of the plate and oriented towards a centre of the plate. The load cells are configured to measure data relating to a force vector at the angled single-axis sensor when the subject applies a force to the plate. A data collection controller is provided for logging time series measurements of the load cells over a time in which the subject applies a force to the plate. The system applies machine learning processing to output the load cell measurements as a three-dimensional ground reaction force on the plate by a subject.

IPC Classes  ?

• G01L 5/16 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force
• G01L 5/161 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes for measuring several components of force using variations in ohmic resistance
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G01G 3/14 - Weighing apparatus characterised by the use of elastically-deformable members, e.g. spring balances wherein the weighing element is in the form of a solid body stressed by pressure or tension during weighing measuring variations of electrical resistance
• G01G 19/44 - Weighing apparatus or methods adapted for special purposes not provided for in groups for weighing persons

Abstract

The present invention relates to a method for increasing the expression and/or promoting correct folding of a heterologous polypeptide of interest in a plant cell, comprising co-expressing the heterologous polypeptide of interest with a polypeptide encoding a mammalian chaperone protein. The invention also relates to plant cells and plants, which either transiently or stably, co-express the heterologous polypeptide of interest and the chaperone protein.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention relates to a method and kit for determining a likelihood of a human subject with asymptomatic tuberculosis (TB) infection or suspected TB infection progressing to active tuberculosis disease, the method comprising detecting a presence or level of a first and a second pair of protein biomarkers selected from Complement Component 9 (C9) and Complement C1q Tumor Necrosis Factor-Related Protein 3 (C1qTNF3); and C9 and Creatine Kinase M- and B-type (CKMB) in a sample from the subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis

Abstract

The invention provides a method for diagnosing and treating tuberculosis (TB). The method comprises testing a urine sample from a subject suspected of having TB for the presence of at least two human-derived biomarkers, of which one is SAA1 and the other is RETN or RBP4. The urine sample can also be tested for the presence of one or more additional biomarkers selected from LILRB4, IL18BP, SERPINA3, CD59, IGLV3.21, IGKV1.17, SAA2, CRP, TSP4, AXA81, A8MUE1, 053764_MYCTU (Rv0567), I6Y0W5_MYCTU (fadE19, Rv2500c), Q79FP1 _MYCTU (PE_PGRS28, Rv1452c), HTPG_MYCTU (htpG, Rv2299c), RPOB_MYCTU (rpoB, Rv0667), EFTU_MYCTU (tuf, Rv0685), ACR_MYCTU (hspX, Rv2031c), CH602_MYCTU (groEL2, Rv0440), CLPP1_MYCTU (clpP1, Rv2461c) and/or CH10_MYCTU (10kDa chaperonin, Rv3418c).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention provides a user-guidance device for informing a required change to a pump volume displacement parameter of a manual drug infusion pump assembly, for use with manually- controlled infusion of a drug into a patient. The user-guidance device comprises a measurement component arranged to measure the pump volume displacement parameter. The device further comprises a computing device arranged to calculate a measured rate of infusion of the drug based on the measured pump volume displacement parameter; and to calculate with reference to said measured rate of infusion and to at least one model selected from the group consisting of pharmacokinetic and pharmacodynamic models, a model-simulated drug concentration in the patient. The computing device may be arranged to derive user-guidance information based on the model-simulated drug concentration. The invention also provides a drug infusion system which includes the disclosed user-guidance device in combination with a manual drug infusion pump assembly.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons

Abstract

A knee brace having an upper part securable about a user's thigh and a lower part securable about the user's lower leg is provided. The upper and lower parts are secured together adjacent the user's knee by a hinge. The knee brace is characterised in that a flexible tensioning element extends between the upper part and the lower part over a lobe which is secured to the upper part adjacent the hinge such that pivoting of the upper and lower parts about the hinge causes the flexible element to engage the lobe about its periphery to cause tension in the flexible element and wherein the lobe is shaped to cause the tension to dynamically increase as the upper part is pivoted relative to the lower part.

IPC Classes  ?

• A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces

Abstract

A motion capture system and method are provided. In a motion capture method, a plurality of motion datasets are accessed. Each motion dataset is associated with a motion sensing unit at which timestamped motion data points of that motion dataset are generated, each motion sensing unit is configured to be in physical contact with a different part of a body of interest. Each timestamped motion data point is timestamped at the motion sensing unit at which it is generated using a clock time that is synchronized across the plurality of motion sensing units. The timestamped motion data points are processed to generate a kinematic model which describes motion of the respective parts of the body of interest.

IPC Classes  ?

• G01S 19/43 - Determining position using carrier phase measurements, e.g. kinematic positioningDetermining position using long or short baseline interferometry
• G01S 19/49 - Determining position by combining or switching between position solutions derived from the satellite radio beacon positioning system and position solutions derived from a further system whereby the further system is an inertial position system, e.g. loosely-coupled
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G01S 19/19 - Sporting applications

Abstract

Systems and methods for object identification are provided. In a method, primary data is received. The primary data is generated by a primary sensor that receives signals that are human perceptible and records a scene. Secondary data generated by a secondary sensor that simultaneously records the same scene is received. The secondary sensor receives signals that are not human perceptible. The primary data is processed to identify object signatures relating to objects present in the scene. The processed primary data is used to train a secondary data-based object identification model configured to identify, in the secondary data, object signatures relating to objects present in the scene. A method includes using the secondary data-based object identification model to process the secondary data to identify object signatures relating to objects present in the scene. A method includes augmenting the processed primary data with the processed secondary data.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G01S 13/86 - Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

The present invention relates to a fusion protein consisting of a scFv linked to a horseradish peroxidase enzyme or to an alkaline phosphatase enzyme by a peptide linker. The fusion protein also includes a histidine tag and optionally an endoplasmic reticulum retention signal. The invention also includes nucleic acids encoding the fusion protein, expression vectors containing the nucleic acids, plant cells transformed with the expression vectors and methods of producing the fusion proteins of the invention.

IPC Classes  ?

• C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

3.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• A61K 31/66 - Phosphorus compounds

Abstract

6-Thio derivatives of D-luciferin, also referred to as D-thioluciferins, having the general structure of Formula (I) are provided. Methods for synthesising D-luciferin, its derivatives, and their related 2-cyanobenzothiazole precursors are also provided. These compounds are commercially valuable due to their application in optical imaging, particularly in bioluminescence imaging.

IPC Classes  ?

• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 49/00 - Preparations for testing in vivo

Abstract

The invention provides an improved method of synthesising derivatives of β-D-glucopyranoside-containing polymers, such as chitin, chitosan, cellulose, amylose, pullulan, curdlan, inulin, guar gum or cyclodextrin. The method includes reacting a polymer of formula (III) with a cyclic imide to form a polymer of formula (I) thereby introducing a nitrogen functionality at the 6-position and providing access to 6-deoxy-6-amino-β-D-glucopyranoside-containing polymers.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 15/06 - Derivatives containing elements other than carbon, hydrogen, oxygen, halogen, or sulfur containing nitrogen
• C08B 37/16 - CyclodextrinDerivatives thereof

Abstract

A system and method for determining currents for injection into or extraction from a power network are provided. In a method conducted at a point of common coupling to the network, Thévenin parameter data structures for each of a Thévenin voltage, resistance and inductance, are compiled. An offset data structure including offset values is compiled for application to corresponding values of the Thévenin voltage data structure to output an offset Thévenin voltage data structure. Offset values are calculated to satisfy physical constraints associated with the network. An optimal point of common coupling power data structure and the offset Thévenin voltage data structure are used to calculate current components for determining current for injection into or extraction from corresponding lines at the point of common coupling to reduce total electrical transmission losses of the network. The method may use the frequency domain and may include using frequency-dependent Thévenin parameters.

IPC Classes  ?

• G05F 1/625 - Regulating voltage or current wherein it is irrelevant whether the variable actually regulated is AC or DC
• G06Q 50/06 - Energy or water supply
• H02J 3/06 - Controlling transfer of power between connected networksControlling sharing of load between connected networks
• H02J 3/46 - Controlling the sharing of output between the generators, converters, or transformers

Abstract

Systems and methods for ensuring data privacy in a data sharing system are provided. A computer implemented method carried out at a host computing system includes: accessing a set of data from a data source including a true element and at least one spurious element so that the host computing system cannot differentiate between the elements; accessing a code which is executable on the set of data; and processing the set of data, including for each element: executing the code on the element to generate a result; computing a hash value of the element; and outputting the result in association with the hash value to a third-party computing system that has access to the true hash value of the true element for identification of the result generated by execution of the code on the true element.

IPC Classes  ?

• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
• G06F 21/64 - Protecting data integrity, e.g. using checksums, certificates or signatures

Abstract

Systems and methods for ensuring data privacy in a data sharing system are provided. A computer implemented method carried out at a host computing system includes: accessing a set of data from a data source including a true element and at least one spurious element so that the host computing system cannot differentiate between the elements to obfuscate the true element from the host computing system. The method includes: accessing a code which is executable on the set of data so as to output multiple results for the elements of the set of data; processing the set of data, including for each element: executing the code on the element to generate a result; computing a hash value of the element; and outputting the result in association with the hash value to a third-party computing system. A third-party computing system has access to the true hash value of the true element for identification of the result generated by execution of the code on the true element.

IPC Classes  ?

• H04L 29/06 - Communication control; Communication processing characterised by a protocol
• H04L 9/40 - Network security protocols
• G06Q 30/018 - Certifying business or products
• G06Q 50/26 - Government or public services
• H04L 9/08 - Key distribution
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system

Abstract

An apparatus and method for the characterization of electricity-producing cells using broadband impedance spectroscopy are provided. A method includes injecting a broadband signal having a plurality of superimposed waveforms at different frequency set points across a frequency range into an electricity-producing cell. A distribution of the frequency set points is determined using a function which, for a predetermined number of frequency set points, spaces lower value frequency set points closer together and higher value frequency set points further apart so as to tune the frequency set point distribution optimally for the cell. One or both of a voltage and current response are measured, including obtaining the response at each frequency set point simultaneously. An impedance of the electricity-producing cell is calculated using the broadband signal and the response. The impedance is used to determine a condition of the electricity-producing cell, including using an impedance response calculated across the frequency range.

IPC Classes  ?

• G01R 31/389 - Measuring internal impedance, internal conductance or related variables
• H02S 50/10 - Testing of PV devices, e.g. of PV modules or single PV cells
• H01L 31/04 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices

Abstract

A method for purifying phycocyanin from a phycocyanin-containing solution is provided. The method comprises a first step of partially purifying the solution by aqueous two-phase separation (ATPS) and a second step of purifying the phycocyanin by ammonium sulfate precipitation. The purified phycocyanin product can in some cases be of a sufficiently pure grade to be used as a food or cosmetic pigment.

IPC Classes  ?

• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C07K 1/14 - ExtractionSeparationPurification
• C07K 1/30 - ExtractionSeparationPurification by precipitation
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 14/405 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from algae

Abstract

Vibrio midaeVibrio midaeVibrio midaeVibrio midae SY9 can be provided on or within an alginate film formed on a support.

IPC Classes  ?

• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

Vibrio midaeVibrio midae SY9 cells, are added to an alginate solution. A gelling agent and the alginate solution are then applied separately but simultaneously to a support to form a gel coating or film encapsulating the probiotic cells. The feed composition is intended for feeding farmed aquatic animals, in particular marine animals which feed on algae. These include abalone and echinoderms such as sea urchins, sea cucumbers, starfish, brittle stars, sand dollars and crinoids.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 20/163 - SugarsPolysaccharides
• A23K 20/24 - Compounds of alkaline earth metals, e.g. magnesium
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
• A23K 40/30 - Shaping or working-up of animal feeding-stuffs by encapsulatingShaping or working-up of animal feeding-stuffs by coating

Abstract

The invention relates to a matrix-mediated algal cell culture system comprising a porous matrix, a microalgal cell culture comprising cells immobilised on the porous matrix, and a vector including a nucleic acid sequence encoding a heterologous polypeptide of interest, wherein immobilisation of microalgal cells on the porous matrix results in the formation of interstitial spaces between the microalgal cells to allow for increased contact of the microalgal cells with the vector compared with a culture of microalgal cells which are not immobilised on a porous matrix, thereby allowing for more efficient transfection of the microalgal cells with the vector. The invention also relates to methods of screening single species of microalgae and mixed ecology samples for the ability to be transfected using the algal cell culture system, and to methods for the production of heterologous polypeptides using the matrix-mediated cell culture system.

IPC Classes  ?

• A01G 33/00 - Cultivation of seaweed
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

Abstract

The field of this invention relates to LRP/LR for use in the treatment and/or prevention of Parkinson's disease (PD). The invention extends to pharmaceutical compositions comprising LRP/LR for use in the treatment of Parkinson's Disease (PD), and extends to a method of maintaining concentration levels of dopamine within a human or animal body.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention provides for a low pressure, low temperature process for the production of middle distillate products, including aviation fuel and diesel, from the hydrocracking of a hydrocarbon feedstock consisting of a mixture of hydrocarbons, wherein a significant fraction of said mixture is C25+ hydrocarbons including hydrocarbons selected from Fischer-Tropsch wax, long chain paraffin and/or olefin, wherein the feedstock may include a water component.

IPC Classes  ?

• C10G 47/18 - Crystalline alumino-silicate carriers the catalyst containing platinum group metals or compounds thereof

Abstract

An auto-injector is provided which includes a housing with a syringe slidably received therein. The syringe has a barrel with a piston movable therein and a needle extending therefrom. The piston is releasably secured to one end of a plunger which is slidably secured within a body in the housing and is operable through a bias provided by a motive source. In use, the plunger moves under the bias from a loaded condition to a discharged condition to move the syringe so that the needle extends from a tip at an injection end of the housing and to slide the piston within the barrel to expel the contents of the syringe. The plunger is held in the loaded condition against the bias by a detent extending from the body and which can be selectively released by operation of an actuator when pressure is applied to the tip.

IPC Classes  ?

• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
• A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic

Abstract

A wireless radio frequency triggered signal acquisition device includes three orthogonal pick up coils in which voltages will be induced by a time varying, spatially varying magnetic field inside a chamber of an MRI scanner. A radio frequency detection circuit detects radio frequency pulses emitted by an MRI scanner and a wireless transmission circuit transmits data from the device, A 3-axis magnetometer is used for measuring magnetic flux in the chamber of the MRI scanner. A processor uses the detected radio frequency pulses to synchronize measurements taken by the magnetometer and pickup coils to a time frame of a gradient driver hardware, thereby matching the measurements to a pulse sequence waveform. The processor further combines measurements of induced voltages in the orthogonal pick up coils and the magnetic flux with the pulse sequence waveform in order to solve for the instantaneous position and orientation of the device.

IPC Classes  ?

• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/58 - Calibration of imaging systems, e.g. using test probes
• G01R 33/02 - Measuring direction or magnitude of magnetic fields or magnetic flux
• G01R 33/07 - Hall-effect devices
• G01R 33/36 - Electrical details, e.g. matching or coupling of the coil to the receiver

Abstract

The present invention relates to methods of producing porcine circovirus (PCV) pseudovirions in plant cells, the plant-produced PCV pseudovirions, a neutralisation assay using the plant-produced PCV pseudovirions and pharmaceutical compositions comprising the plant produced PCV pseudovirions. In particular, the method of the invention relates to introducing expression vectors, replicating vectors and nucleic acids into the plant cell and allowing for expression of capsid proteins and replication of the replicating vector. The expressed PCV capsid polypeptides assemble, together with a single-stranded copy of the replicating vector and encapsidate it as a pseudogenome to produce a PCV pseudovirion.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A61K 39/12 - Viral antigens

Abstract

A sensor for monitoring utility poles includes a sensing module to detect a physical quantity from a utility pole or a conductor supported by a utility pole to which the sensor is attached in use. A power supply supplies power to the device and a memory for storing sensor data. A communications module is used for transmitting and receiving sensor data to and from one or more sensors which are attached to other utility poles located adjacent to or nearby the utility pole. A processor uses the detected sensor data together with received sensor data to calculate if the utility pole to which the sensor is attached has changed its physical condition, and wherein if the processor calculates that the utility pole to which the sensor is attached has changed its physical condition, a message is transmitted via the communications module to a remote server.

IPC Classes  ?

• H02J 13/00 - Circuit arrangements for providing remote indication of network conditions, e.g. an instantaneous record of the open or closed condition of each circuitbreaker in the networkCircuit arrangements for providing remote control of switching means in a power distribution network, e.g. switching in and out of current consumers by using a pulse code signal carried by the network
• G01R 19/25 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof using digital measurement techniques
• G01R 22/06 - Arrangements for measuring time integral of electric power or current, e.g. electricity meters by electronic methods

Abstract

The present invention relates to a stabilised SOD-homolog (SODis) gene of SEQ ID NO:2 and recombinant viruses comprising the gene. The invention also relates to a recombinant lumpy skin disease virus (LSDV) wherein a gene encoding a SOD-homolog polypeptide has been inactivated by deletion from the viral genome. The invention further relates to pharmaceutical compositions comprising the recombinant viruses and to the use of the recombinant viruses in methods of preventing a disease in a subject.

IPC Classes  ?

• A61K 39/275 - Poxviridae, e.g. avipoxvirus

Abstract

This invention relates to a neutron detector (10), and more particularly but not exclusively to a neutron detector utilizing organic scintillator materials. The invention also extends to a method of determining the direction from which the neutron radiation emanates. The neutron detector (10) includes a plurality of scintillators (30), at least one photomultiplier (24) associated with each scintillator; and at least one moderator (40). There is provided for the scintillators to have parallel longitudinal axes, with the moderator located between the scintillators. The scintillators are parallel to and spaced about a longitudinal axis of the moderator, and the moderator is configured at least partially to shield the scintillators from one another.

IPC Classes  ?

• G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation
• G01T 3/06 - Measuring neutron radiation with scintillation detectors

Abstract

The present invention relates to a method for producing a recombinant HIV glycoprotein polypeptide in a plant and to trimeric complexes of the recombinant, plant-produced HIV glycoprotein polypeptide which mimic the native HIV Env complex. The invention also relates to nucleic acids encoding the recombinant polypeptides, expression vectors containing the aforementioned nucleic acids and to pharmaceutical compositions, uses and methods of eliciting an immune response against HIV in a subject using the recombinant polypeptides and trimeric complexes.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• C07K 14/16 - HIV-1
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention relates to a method and kit for determining a likelihood of a human subject with asymptomatic tuberculosis (TB) infection or suspected TB infection progressing to active tuberculosis disease, the method comprising detecting a presence or level of a first and a second pair of protein biomarkers selected from Complement Component 9 (C9) and Complement C1q Tumor Necrosis Factor-Related Protein 3 (C1qTNF3); and C9 and Creatine Kinase M- and B-type (CKMB) in a sample from the subject.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention provides a gene signature for use in determining a likelihood of a latent tuberculosis (TB) infection in a subject transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, and optionally also GAS6 and/or CD1C. Expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the above genes are calculated (e.g. SEPT4:BLK, SEPT4:CD1C, GAS6:BLK and/or GAS6:CD1C). A score is assigned to each ratio, the score being indicative of the likelihood of the latent TB infection transitioning into active TB disease, based on the ratio for the respective gene pair. The subject can be identified as having a latent TB infection that is likely to transition into active TB disease or that is not likely to transition into active TB disease based on the score or on the average of the scores.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A motion capture system and method are provided. In a motion capture method, a plurality of motion datasets are accessed. Each motion dataset is associated with a motion sensing unit at which timestamped motion data points of that motion dataset are generated, each motion sensing unit is configured to be in physical contact with a different part of a body of interest. Each timestamped motion data point is timestamped at the motion sensing unit at which it is generated using a clock time that is synchronized across the plurality of motion sensing units. The timestamped motion data points are processed to generate a kinematic model which describes motion of the respective parts of the body of interest.

IPC Classes  ?

• G01S 19/19 - Sporting applications
• G01C 21/16 - NavigationNavigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigatedDead reckoning by integrating acceleration or speed, i.e. inertial navigation
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G01S 19/49 - Determining position by combining or switching between position solutions derived from the satellite radio beacon positioning system and position solutions derived from a further system whereby the further system is an inertial position system, e.g. loosely-coupled
• G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings

Abstract

Systems and methods for object identification are provided. In a method, primary data is received. The primary data is generated by a primary sensor that receives signals that are human perceptible and records a scene. Secondary data generated by a secondary sensor that simultaneously records the same scene is received. The secondary sensor receives signals that are not human perceptible. The primary data is processed to identify object signatures relating to objects present in the scene. The processed primary data is used to train a secondary data-based object identification model configured to identify, in the secondary data, object signatures relating to objects present in the scene. A method includes using the secondary data-based object identification model to process the secondary data to identify object signatures relating to objects present in the scene. A method includes augmenting the processed primary data with the processed secondary data.

IPC Classes  ?

• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

This invention relates to an endoscopic device, and more particularly but not exclusively to an endoscopic device suitable for use in diagnostic and/or surgical procedures. The endoscopic device includes a base and a shaft extending from the base. The shaft is at least partially flexible and includes a bending section that is selectively displaceable between a straight configuration and a bent configuration. The endoscopic device also includes an actuation arrangement for selectively displacing the bending section between the straight and bent positions. The actuation arrangement includes at least one actuator which is at least partially made from a shape memory alloy, and which is configured to displace the bending section of the shaft when electric current is passed therethrough. The actuator is located inside the base of the device.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/005 - Flexible endoscopes

Abstract

This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R1is phenyl substituted with two occurrences of isopropyl, R2is Cl, and R3222222222222222233.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• A61P 35/00 - Antineoplastic agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/282 - Platinum compounds
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
• A61K 31/28 - Compounds containing heavy metals
• A61P 35/00 - Antineoplastic agents